Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs ResMed Inc. — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $118.73, while ResMed Inc. trades at $219.5 (market cap $31.73B). The key difference: ResMed Inc. pays a 1.2% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| QQQE | RMD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $283.28 |
52-Week Low | $96.06 | $182.82 |
Market Cap | — | $31.73B |
Enterprise Value | — | $31.08B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE trades at $119.78, down 0.8% on the day, with a neutral technical signal overall. The ETF provides equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights the potential inclusion of SpaceX in the underlying index, which could drive new investor interest. Technical indicators show mixed signals with bullish moving averages but neutral oscillators.
The outlook for QQQE remains tied to Nasdaq-100 performance, with equal weighting offering defensive characteristics during market rotations. Key risks include tech sector volatility and index composition changes. The ETF's structure provides diversification benefits for investors seeking Nasdaq exposure without heavy concentration in mega-cap tech names.
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
